Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Non-Current Debt: 2012-2022

Historic Non-Current Debt for Altimmune (ALT) over the last 9 years, with Dec 2022 value amounting to $4.6 million.

  • Altimmune's Non-Current Debt was N/A to $14.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.4 million, marking a year-over-year change of. This contributed to the annual value of $4.6 million for FY2022, which is 215.06% up from last year.
  • Altimmune's Non-Current Debt amounted to $4.6 million in FY2022, which was up 215.06% from $1.5 million recorded in FY2021.
  • Over the past 5 years, Altimmune's Non-Current Debt peaked at $4.6 million during FY2022, and registered a low of $1.5 million during FY2021.
  • For the 3-year period, Altimmune's Non-Current Debt averaged around $2.6 million, with its median value being $1.8 million (2020).
  • Its Non-Current Debt has fluctuated over the past 5 years, first plummeted by 59.51% in 2018, then spiked by 215.06% in 2022.
  • Altimmune's Non-Current Debt (Yearly) stood at $1.9 million in 2018, then climbed by 0.69% to $1.9 million in 2019, then declined by 1.95% to $1.8 million in 2020, then declined by 20.48% to $1.5 million in 2021, then spiked by 215.06% to $4.6 million in 2022.